We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Oluwarantimi Adetunji, 202-923-5996, oluwarantimi.adetunji@hhs.gov. Content will be updated pending the outcome of the Section 508 review.